Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Agulnik

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
ESMO Open|June 29, 2024
Current unmet needs in locally advanced (unresectable) or metastatic dedifferentiated liposarcoma, the relevance of progression-free survival as clinical endpoint, and expectations for future clinical trial design: an international Delphi consensus reportP Schöffski, R L Jones, M Agulnik, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcomaM A Dickson, M R Mahoney, W D Tap, et al.
Medrxiv : the Preprint Server for Health Sciences|June 12, 2025
A first-in-human, Phase 1/2a, open-label study of SQ3370, a first-in-class doxorubicin-based click chemistry therapeutic, in patients with advanced solid tumorsS P Chawla, E Abella, S Wieland, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2016
A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomasM Agulnik, R L B Costa, M Milhem, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
ESMO Open|June 29, 2024
Current unmet needs in locally advanced (unresectable) or metastatic dedifferentiated liposarcoma, the relevance of progression-free survival as clinical endpoint, and expectations for future clinical trial design: an international Delphi consensus reportP Schöffski, R L Jones, M Agulnik, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcomaM A Dickson, M R Mahoney, W D Tap, et al.
Medrxiv : the Preprint Server for Health Sciences|June 12, 2025
A first-in-human, Phase 1/2a, open-label study of SQ3370, a first-in-class doxorubicin-based click chemistry therapeutic, in patients with advanced solid tumorsS P Chawla, E Abella, S Wieland, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2016
A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomasM Agulnik, R L B Costa, M Milhem, et al.
Pageof 2